Research at MD Anderson
Scroll Ahead
Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
FY19 Research Quick Facts
$902M
research spending
1,364
clinical trials
1,600
research trainees
MD Anderson’s dedication to translating scientific knowledge into clinical care is evidenced in this year’s Quick Facts.
See the full 2020 Quick FactsDepartments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Research Areas
Since 1941, MD Anderson has been home to some of the brightest minds across a variety of cancer research areas.
Resources
MD Anderson provides research tools and resources to fuel the discoveries of our scientists.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program® was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.
Learn more about the Moon Shots ProgramResearch Highlights
Research Seminars
A personal mission
CAR T-cell trial
Recovery research
TIL therapy
HGSC treatment
Training collaboration
Combination therapy
NEWSROOM
MD Anderson genetics expert Guillermina Lozano elected to American Academy of Arts and Sciences
MD Anderson researcher and chair of Genetics, Guillermina Lozano, Ph.D., is one of the 276 new members elected to the American Academy of Arts and Sciences’ 2020 cohort. Lozano is widely recognized for her work studying the p53 tumor suppressor pathway gene.
Research during COVID-19
How the MD Anderson research community is persevering during
COVID-19